Printer Friendly

Cellegy issued patent covering use of potassium channel openers to treat anorectal disorders.

Cellegy Pharmaceuticals, Inc. (S. San Francisco, CA; 650-616-2200) announced that the United States Patent and Trademark Office has issued a patent (United States 6,395,736) that covers methods of treating anorectal disorders by administering certain concentrations of topical potassium channel openers to the anorectal region in order to decrease abnormally high pressure of the anal sphincter muscle. The disorders disclosed in the patent include anal fissures, hemorrhoids and constipation.

Potassium channel openers help smooth muscle relaxation and, therefore, are anticipated to provide useful medical options in treating anorectal disorders. Data obtained from in vivo experiments demonstrated effective internal anal sphincter relaxation with administration of various potassium channel openers. These agents are expected to compliment Cellegesic's (nitroglycerin ointment) effect on smooth muscle relaxation.

Dr. Vivien Mak, Vice President of Research at Cellegy, commented, "Over the past two weeks, Cellegy has been issued two important United States patents (covering the use of PDE inhibitors and potassium channel openers) that result from our ongoing efforts to develop products for the treatment of fissures and hemorrhoids. Such products are expected to deepen our Cellegesic product line through the development of new dosage forms, line extensions and product improvements in order to maximize the commercial potential of Cellegy's investment in this greatly underserved therapeutic area. Our patent portfolio in this field has been significantly strengthened by the two recently issued patents."

Cellegy is a specialty biopharmaceutical company focused on the areas of gastroenterology, sexual dysfunction in males and females, and various women's health conditions.

Cellegy has a significant pipeline of late stage products. Apart from Cellegesic, which is the subject of ongoing discussions with the FDA regarding requirements for marketing approval in the United States, the company recently announced that it has filed an NDA (New Drug Application) on its patented product Tostrex (testosterone gel), for the treatment of male hypogonadism. Another product in Cellegy's pipeline, Tostrelle, a transdermal testosterone gel for the treatment of female sexual dysfunction entered into Phase II/III clinical testing during the first quarter of 2002.

Additional pipeline products include nitric oxide donors for the treatment of dyspareunia (a form of sexual dysfunction) in females, Raynaud's Disease, Restless Leg Syndrome, and prostate cancer, as well as products for the treatment of male erectile dysfunction. Cellegy is currently exploring various partnering opportunities for these patent protected product candidates in the United States and international markets.
COPYRIGHT 2002 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 1, 2002
Previous Article:Endovasc files patent application for angiogenesis stent.
Next Article:Introgen's mda-7 gene therapeutic receives patent.

Related Articles
NeoTherapeutics announces issuance of new patent on treatment of neurodegenerative diseases with neurotrophic factors.
ICAgen obtains exclusive rights to novel ion channel drug discovery technology from Rockefeller University.
Cambridge NeuroScience receives two United States patents and three United States patent allowances.
Cellegy Pharmaceuticals granted anogesic patent in Europe.
Avigen granted gene therapy patent for intravenous delivery of Aav vectors.
Oppositions filed to Cellegy hemorrhoid treatment patent in Europe.
PDI settles lawsuit with Cellegy.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters